A study by researchers from Huntsman Cancer Institute found that about 6 percent of colorectal cancers are missed during colonoscopies, particularly in patients over 65 and those with a family history of the disease. The cancers may develop rapidly after the procedure or be overlooked due to factors like polyp size or location.
Cologuard detects precancer and cancer with high sensitivity rates, surpassing existing non-invasive tests, offering a user-friendly approach to expand screening effectiveness and curb colorectal cancer rates. The test's accuracy has transformed how we think about colorectal cancer screening.
A new non-invasive genetic test detected 92% of colon cancer cases, outperforming a traditional fecal immunochemical test in asymptomatic participants. The test's high sensitivity could lead to increased screening rates and reduced deaths from colorectal cancer.
A new multi-target stool DNA test detects 92.3% of colon cancers, outperforming the current standard fecal immunochemical test. The test identified advanced precancerous polyps nearly 70% of the time compared to 45% for the existing method.
A recent study found that colon cancer incidence rates have dropped by 30 percent in the US among adults 50 and older due to widespread colonoscopy adoption. Colonoscopy use has almost tripled among adults ages 50-75, leading to significant declines in mortality rates as well.
The American Gastroenterological Association highlights significant new colorectal cancer (CRC) research in Clinical Gastroenterology and Hepatology and Gastroenterology. Studies reveal the impact of patient factors on colonoscopy preparation quality, as well as the relationship between dietary fiber intake and reduced CRC risk.
A study published in The Journal of Experimental Medicine reveals that gut microbes contribute to the development of intestinal tumors, leading to colorectal cancer. Disrupting gut bacteria with antibiotics prevented polyp formation in mice, suggesting a link between inflammation and tumor growth.
A new study found that despite improved cancer treatments, survival rates for Blacks and Hispanics have not increased significantly. The disparity is largely attributed to factors such as poorer health and lower socioeconomic status, leading to barriers in healthcare access.
A new evidence review finds that fecal immunochemical tests (FITs) detect about 79% of colorectal cancers and correctly identify 94% of patients without cancer. The test is simple, can be done at home, and can save lives, making it a great tool for assessing which patients have cancer and which do not.
An international study has developed a refined method to identify people at risk for certain inherited cancers associated with Lynch syndrome. The study uses genetic data from thousands of variants identified worldwide to classify variants of unknown significance and improve genetic counseling for families.
A study found that follow-up tests improved the rate of surgical treatment for cancer recurrence in patients who had undergone curative surgery for primary colorectal cancer. The benefits were seen in both computed tomography and carcinoembryonic antigen screening methods, with no advantage in combining these tests.
A new tool called CRC-PRO predicts an individual's risk of colorectal cancer, providing a more accurate estimate than current guidelines. The calculator includes gender, race, and family history as calculable risk factors, enabling physicians to identify high-risk patients for earlier screenings.
A University of Colorado Cancer Center study found that ALK and ROS1 gene rearrangements, known to drive subsets of lung cancer, are also present in some colorectal cancers. This implies that drugs used to target ALK and ROS1 in lung cancer may have applications in treating a subset of colorectal cancer patients.
A €6 million European study led by Queen's University aims to develop new diagnostics and therapies for bowel cancer. The research will investigate two major genetic factors contributing to the aggressive spread of colorectal cancer, with the goal of improving patient survival rates.
A new study found that decreased bacterial diversity in the gut is associated with an increased risk of colorectal cancer. The research, published in the Journal of the National Cancer Institute, suggests that a reduced variety of gut microbiota may contribute to the development of CRC.
A large epidemiological study discovered a clear association between gut bacteria and colorectal cancer. Colorectal cancer patients had fewer beneficial bacteria and more harmful bacteria than healthy individuals.
AUC San Diego study reveals racial inequality in cancer treatment access, resulting in 15% higher mortality for African-American patients. Despite receiving similar treatments, black patients are less likely to receive primary tumor surgery and chemotherapy.
A study by Arizona State University researchers links CXCR2 to tumor formation, growth, and progression in colon cancer. The genetic culprit is implicated in recruiting immune cells that evade the immune response, providing a new clue for developing therapeutic targets.
New research published in The Journal of Nuclear Medicine found that radioembolization therapy can extend survival for patients with colorectal cancer liver metastases by approximately 50 percent. This treatment option has shown promise as a life-extending treatment for salvage patients who have failed current treatments.
Researchers at University of Copenhagen have discovered a potential treatment for colorectal cancer by targeting the TOP2A gene aberration. The new treatment has shown promise in reducing treatment time and cost, with an estimated efficiency rate of 10% in patients with this gene defect.
A new study published in mBio found that transferring gut microbes from mice with colon tumors increased the risk of tumors in germ-free mice. The research indicates that inflammation and interactions between gut microbiota play a critical role in tumor formation.
A study by Penn State researchers found that US citizenship increases a woman's likelihood of receiving mammograms and cancer tests. Foreign-born non-citizens have significantly lower odds of being screened for colorectal, breast, and cervical cancers compared to U.S.-born citizens.
Researchers at the McGill University Health Centre have identified genetic changes in the colon lining that could be used as biomarkers for early diagnosis of colorectal cancer. The study, published online in Cancer Prevention Research, has implications for the nearly one million people diagnosed annually worldwide.
Men who spend more than 11.38 hours a day engaged in sedentary behaviors are 45% more likely to experience colorectal adenoma recurrence compared to those who spend fewer than 6.90 hours. The study found that sedentary behavior independently contributes to increased cancer risk beyond the accompanying reduction in physical activity.
Researchers found that tumors may switch dependence from VEGF-A to related growth factors like VEGF-C, VEGF-D, and placental growth factor when targeted by bevacizumab. This change allows colorectal cancer to continue growing despite the blockage of VEGF-A.
A new study found a significant gene-diet interaction between processed meat consumption and genetic variants associated with reduced risk of colorectal cancer. The study suggests that understanding these interactions may lead to targeted prevention strategies for individuals at higher risk.
A common genetic variant affecting 1 in 3 people increases colorectal cancer risk from red and processed meat consumption. Eating more fruits and veggies may lower risk for some individuals with a specific genetic variation.
Researchers at UAlberta have discovered a potential new treatment for colitis by using a leukemia drug to reverse symptoms in lab tests. The discovery suggests that inhibiting inflammation can reduce the likelihood of patients with ulcerative colitis developing colorectal cancer later in life.
A recent study found that current national screening guidelines for colon cancer may miss up to 10 percent of cases in first-degree relatives. The research examined nearly 127,000 individuals who underwent colonoscopy in Utah between 1995 and 2009.
A CU Cancer Center study found that young patients with metastatic colorectal cancer have a higher risk of treatment failure and worse survival rates compared to middle-aged patients. The study analyzed data from over 20,000 patients and showed a significant increase in disease progression and death among those under 40.
Research found that patients with more primary care visits have lower colorectal cancer incidence and mortality rates. Increasing access to primary care may reduce the national burden of CRC.
A large-scale analysis of 20,034 patients found that young age is associated with worse overall survival and progression-free survival in those with metastatic colorectal cancer. The study suggests that these patients have a poorer prognosis if their disease has metastasized.
A recent study found that colorectal cancer screening programs in European countries have a significant impact on reducing mortality rates. The researchers analyzed data from 11 European countries and found that the scope and take-up of CRC screening activities were strongly related to the reductions in death rates.
A new study published in the New England Journal of Medicine reinforces the value of colonoscopy screening for colorectal cancer prevention. Researchers analyzed data from nearly 90,000 people and found that colonoscopy lowered cancer-occurrence rates in both the distal and proximal sections of the colorectum.
A 22-year study of 88,902 participants found that colonoscopy reduced death from colorectal cancer by up to 40% compared to sigmoidoscopy. The study suggests that colonoscopy is the most effective screening method for preventing colorectal cancer.
A study published in the New England Journal of Medicine found that colonoscopy significantly reduces the risk of developing or dying from colorectal cancer compared to sigmoidoscopy. The comprehensive exam visualizes the entire colon, reducing risk throughout its entirety.
A large study found that colonoscopy screening can prevent up to 40% of colorectal cancers, with more frequent intervals recommended for those with a personal history of adenoma or family history of colorectal cancer. The study also suggests that sigmoidoscopy alone is insufficient for reducing the incidence of proximal colon cancer.
Researchers aim to understand and address disparities in CRC screenings for African Americans, with a focus on developing effective intervention strategies. The study seeks to compare the effectiveness of narrative and didactic approaches to educating African Americans about screening.
A new study suggests a hybrid screening strategy that combines annual or biennial fecal immunological tests with a single colonoscopy at age 66 may reduce colorectal cancer incidence and mortality while lowering costs. This approach can deliver health benefits comparable to current strategies, making it an attractive alternative.
Two studies link fusobacteria from mouth to colorectal cancer formation by stimulating bad immune responses and activating cancer growth genes. Fusobacteria rely on FadA molecule to attach to and invade human cells, promoting tumor growth.
A new study found a positive link between diet high in sugar and fat and an increased risk of colorectal cancer. Researchers identified new dietary risk factors, including fizzy drinks, cakes, and high-energy snack foods, that were associated with an increased risk of bowel cancer.
Long-term aspirin use has been linked to reduced colorectal cancer risk, but alternate-day dosing shows increased gastrointestinal bleeding. Electronic health records adoption led to ambulatory cost savings of 3% per member per month and reductions in radiology costs in experimental pilot communities.
A large study found that regular aspirin use is associated with a lower risk of BRAF-wild-type colorectal cancer, but not BRAF-mutated cancer. The researchers also observed a significant risk reduction for BRAF-wild-type cancer with increasing aspirin tablets per week and longer duration of use.
A new study found that virtual colonoscopy screenings can be safely delayed for women by 5-10 years compared to men, with minimal impact on cancer detection rates. The findings suggest that women under 55 may only need to undergo screening every 10 years, while those over 60 can wait up to 5 years longer.
Researchers have identified a new biomarker for colorectal cancer detection using serum DNA analysis, detecting 87% of all stages of CRC cases. The SDC2 methylation test has high sensitivity and specificity, making it a promising non-invasive alternative to colonoscopy.
Researchers found a strong correlation between MET protein levels and epithelial-mesenchymal transition (EMT) phenotype in colorectal cancer. This association suggests that MET protein may serve as a surrogate biomarker for aggressive colon cancer, potentially enabling personalized treatment approaches.
A new LSUHSC paper has been selected as the Best Paper of the Year by the National Cancer Registrars Association for its innovative evaluation of cancer stages. The study found that lung and prostate cancers had the highest percentages of unknown stages, with non-hospital reporting sources being a key predictor.
A novel transcriptome-based classification of colon cancer has been developed, improving disease stratification based on clinicopathological variables and common DNA markers. The analysis identified six molecular subtypes associated with distinct clinical and pathological characteristics.
A new smartphone application has been shown to significantly improve colonoscopy preparation by providing personalized guidance and reminders for patients. The study found that 84% of individuals who used the app received a good score on the Boston Bowel Preparation Scale, compared to 56% of those who did not use the app.
Researchers examined new methods for managing digestive health through diet and lifestyle changes. Vitamin D supplementation was found to significantly relieve symptoms of Crohn's disease, including muscle strength and fatigue.
Depressive symptoms observed in cancer survivors between one and ten years after diagnosis increase the risk of premature death. Cancer survivors with depression are twice as likely to have died early compared to those without depression.
The UIC Center for Clinical and Translational Science has selected six research projects to receive $30,000 per year pilot grants. These grants aim to support the development of new ideas and generate preliminary data for applying for highly competitive grants from outside sources.
A mathematical model of tumor growth inhibition predicts treatment effect with bevacizumab for patients with metastatic colorectal cancer. The best metric for predicting overall survival was time to tumor growth, which worked equally well in Western and Chinese patients.
A study found that long sleep duration is associated with an increased risk of developing colorectal cancer, particularly among individuals who are overweight or snore regularly. The researchers suggest that obstructive sleep apnea may contribute to this association by reducing sleep quality and increasing tumor growth.
Researchers discovered that abnormal histone protein modification impairs DNA repair machinery, leading to a potential new way of detecting colorectal cancers. The study, published in Cell, reveals a novel mechanism explaining the root cause of some forms of colorectal cancers.
Researchers at Mount Sinai have identified a soy-based compound, genistein, that can inhibit tumor cell growth and block Wnt signaling hyperactivity in colorectal cancer. Genistein has shown promise as an adjunctive treatment for metastatic colorectal cancer when used in combination with chemotherapy.
Researchers found that cosmic radiation impairs the ability of cells in the intestines of mice to eliminate oncogenic proteins, substantially increasing development of colorectal tumors. The study suggests that space travelers may be at increased risk of developing colorectal cancer due to prolonged exposure to cosmic radiation.
A Phase III clinical trial found that adding cetuximab to chemotherapy enables previously inoperable patients to undergo surgery, tripling the rates of successful surgery for liver metastasis. The combination also extends median overall survival by 10 months compared to chemotherapy alone.
A Penn Medicine study found that computed tomography colonography (CTC) was used appropriately in asymptomatic Medicare patients. The study suggests that CTC may have expanded colorectal cancer screening beyond the population screened with standard optical colonoscopy.
The GIE special issue discusses the management of serrated colon polyps, including risk factors and management recommendations. Prophylactic clip closure is shown to reduce delayed postpolypectomy hemorrhage in large sessile or flat lesions.